NCT04349683

Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis

Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis：A Multicenter Randomized Controlled Clinical Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 332 (estimated)
• Sponsor: Jemincare · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, double-blind randomized controlled study to assess the efficacy and safety of Jinshuibao for patients with CKD due to glomerulonephritis, with a planned follow-up of 48 weeks.

Detailed description

Previous studies have shown that cordyceps sinensis can act on several immune response pathways. Jinshuibao capsule, which is composed of fermented cordyceps sinensis powder (Cs-4) , has shown therapeutic effects in chronic kidney disease (CKD) according to small sample exploratory studies. Here, we conduct a prospective, double-blind randomized controlled study to assess the efficacy and safety of Jinshuibao for patients with CKD due to glomerulonephritis.

Conditions

• Chronic Kidney Disease Stage 3B
• Chronic Kidney Disease stage4
• Glomerulonephritis

Interventions

Type	Name	Description
DRUG	Jinshuibao	6 capsules at a time, 3 times a day (tid).
DRUG	Placebo	6 capsules at a time, 3 times a day (tid).

Timeline

• Start date: 2020-04-30
• Primary completion: 2021-08-30
• Completion: 2021-10-30
• First posted: 2020-04-16
• Last updated: 2020-04-20